Obesity and metabolic syndrome: Clinical and therapeutic review;Obesità e sindrome metabolica: Considerazioni cliniche e terapeutiche

Monaldi Archives for Chest Disease - Cardiac Series

Volumn 64, Issue 1, 2005, Pages 45-49

  Cuppini, Andrea ^a   Matteini, Paola ^a  

^a BELLARIA HOSPITAL   (Italy)

Author keywords

Metabolic syndrome; Obesity

Indexed keywords

ANTIOBESITY AGENT;

BODY MASS; CARDIOVASCULAR RISK; CLINICAL FEATURE; COGNITIVE THERAPY; DIET THERAPY; DISEASE CLASSIFICATION; DYSLIPIDEMIA; HEALTH EDUCATION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X; OBESITY; PHYSIOTHERAPY; PSYCHOTHERAPY; REVIEW; SOCIAL SUPPORT; SURGICAL TECHNIQUE; WEIGHT REDUCTION;

EID: 23844496270     PISSN: 11220643     EISSN: None     Source Type: Journal    
DOI: 10.4081/monaldi.2005.612     Document Type: Review

References (23)

1. Linee Guida Italiane Obesità: identificare, valutare, trattare. LiGIO 1999
2. Ukkola O, Bouchard C. Role of candidate genes in the responses to long-term overfeeding: review of findings. Obes Rev 2004; 5 (1): 3-12.
3. Bastard JP, Pieroni L. Plasma plasminogen activator inhibitor 1, insulin resistance and android obesity. Biomed Pharmacother 1999; 53 (10): 455-61.
4. Yudkin JS, Kumari M, Humphries SE, Mohamed-Alì V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000; 148 (2): 209-14.
5. Stears AJ, Byrne CD. Adipocyte metabolism and the metabolic syndrome. Diabetes Obes Metab 2001; 3 (3): 129-42.
6. Mancini M. Ricerca Roche; 2000; 27, 13-15.
7. Seidell JC. Ricerca Roche; 2000; 27, 16-18.
8. Third Report of the National Cholesterol Education Program (NCPE) Expert Panel On Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III) U.S. Department of Health and Human Services Public Health Service National Institutes of Health National Heart and Blood Institute NIH Pubblication No. 01-3670, May 2001.
9. Lamarche B, Lemieux I, Despres JP. The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects. Diabetes Metab 1999; 25 (3): 199-211.
10. Despres JP, Lamieux I, Dagenais GR, Cantin B, Lamarche B. HDL-cholesterol as a marker of coronary heart disease risk: the Quebec cardiovascular study. Atherosclerosis 2000; 153 (2): 263-72.
11. Grundy SM. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation 2002; 12; 106 (20): 2526-9.
12. Despres JP. Drug treatment for obesity. We need more studies in men at higher risk of coronary events. BMJ 2001; 9; 322 (7299): 1379-80.
13. Eckel RH, Barouch WW, Ershow AG. Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on the pathophysiology of obesity-associated cardiovascular disease. Circulation 2002; 18; 105 (24): 2923-8.
14. Ahima RS, Osey SY. Molecular regulation of eating behavior: new insights and prospects for therapeutic strategies. Trends Mol Med 2001; 7 (5): 205-13.
15. Goldfine AB, Kahn CR. Adiponectin: linking the fat cell to insulin sensitivity. Lancet 2003; 362 (9394): 1431-2.
16. Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 2003; 112 (12): 1785-8.
17. Grodstein F, Levie R, Try L, Spencer T et al. Three-year follow-up of participants in a commercial weight loss program. Can you keep it off? Arch Intern Med 1996; 156 (12): 1302-6.
18. Anderson JW, Konz EC. Obesity and disease management: effects of weight loss on comorbid conditions. Obes Res 2001; Suppl 4: 326S-334S.
19. Williamson DF, Pamuk E, Thun M et al. Prospective study of intentional weight loss and mortality in over-weight white men aged 40-64 years. Am J Epidemiol 1999; 149 (6): 491-503.
20. Tuomilehto J, Lindstrom J, Erijksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344 (18): 1343-50.
21. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346 (6): 393-403.
22. Enzi G. et al. In: Bosello O: Obesità. Kurtis Ed. 1999; 405.
23. Centro di Studio e Ricerca sull'Obesità, Dipartimento di Scienze Precliniche, Università di Milano: Obesità, sindrome plurimetabolica e rischio cardiovascolare: Consensus sull'inquadramento diagnostico-terapeutico. Con il Patrocinio del Ministero della Salute.